Rovadicitinib

AstraZeneca has secured ex-China rights to TQC3721, an inhaled dual PDE3/4 inhibitor for COPD, in a deal worth USD 200 million upfront and up to USD 2.1 billion in total potential value. The molecule, discovered and developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Hong Kong-listed Sino Biopharmaceutical Limited (HKEX: 1177), has generated Phase IIb data in COPD and is currently in Phase III in China. The deal is the second major out-licensing transaction CTTQ has executed in 2026, following Sanofi’s acquisition of global rights to rovadicitinib in a deal worth up to USD 1.53 billion in March. Under the agreement, AstraZeneca receives an exclusive license to develop, manufacture, and commercialize TQC3721 outside China. AstraZeneca also gains exclusive global rights for certain future CTTQ development programs — a forward-looking provision that adds pipeline optionality beyond the core single-asset structure. CTTQ retains full China rights and continues independent development of both the nebulized formulation (currently in Phase III) and a dry powder inhaler formulation (in Phase II). The deal is subject to customary closing conditions including regulatory clearances. Milestones of up to USD 1.9 billion span development, regulatory, and sales triggers; specific breakdowns were not disclosed. Royalties are tiered and reach up to double-digit percentages on annual net sales. TQC3721 is a small molecule inhaled dual PDE3/4 inhibitor. By simultaneously blocking PDE3 and PDE4, the molecule is designed to produce bronchodilatory effects — historically associated with PDE3 inhibition — alongside anti-inflammatory activity driven by PDE4 inhibition, in a single inhaled agent. Phase IIb data in COPD were presented at the European Respiratory Society congress in September 2025, where the nebulized formulation demonstrated a profile described by the company as potentially best-in-class. TQC3721’s most direct competitive reference point is ensifentrine (Ohtuvayre), a nebulized PDE3/4 inhibitor developed by Verona Pharma that received US FDA approval in June 2024 and was subsequently acquired by Merck for USD 10 billion in 2025. GSK licensed a competing Chinese-originated inhaled PDE3/4 inhibitor, HRS-9821 from Hengrui Pharma, as part of a broader 12-program deal in July 2025 worth up to USD 12 billion in aggregate. That deal makes HRS-9821 TQC3721’s most direct clinical competitor, with both assets originating from Chinese developers, both licensed ex-China to top-three global respiratory companies, and both targeting COPD with the same dual mechanism. AstraZeneca has been executing a systematic Chinese asset acquisition strategy across modalities in 2026. The company paid a USD 1.2 billion upfront payment to CSPC Pharmaceutical under a long-acting peptide collaboration, and separately entered a collaboration with CSPC for siRNA candidates targeting renal disease worth up to USD 1.77 billion. The TQC3721 transaction extends that pattern into respiratory, a therapeutic area where AstraZeneca’s existing franchise — anchored by Breztri (budesonide/glycopyrrolate/formoterol) and the anti-TSLP biologic tezepelumab — does not include an approved PDE3/4 inhibitor. The addition of TQC3721 would occupy a mechanistically distinct niche from both AstraZeneca’s existing inhaled triple combination and its biologic respiratory assets. For Sino Bio, the deal is the third announced partnership with a top-five global pharmaceutical company in under three months in 2026 — Sanofi in March, GSK (for bepirovirsen commercialization in China and, on the same day as this announcement, for Trelegy Ellipta and Anoro Ellipta commercialization rights in mainland China), and now AstraZeneca. That sequencing is deliberate: each deal increases CTTQ’s negotiating leverage and public credibility as a preferred partner for multinational respiratory and specialty pharma companies operating in or out of China. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

iStock, Veronika Oliinyk Kali Therapeutics’ T cell engager, for which Sanofi is initially paying $180 million, could potentially be developed for a range of B cell–driven autoimmune disorders. Sanofi is partnering with California’s Kali Therapeutics to advance a tri-specific antibody targeting autoimmune disorders, continuing the pharma’s recent dealmaking spree in the immunology space. Sanofi is putting down $180 million in upfront and near-term payments for Kali’s KT501, a novel T cell engager, according to a Monday news release . The pharma has also committed up to $1.05 billion in development and commercial milestones. Kali, meanwhile, will also be eligible to receive tiered royalties on sales in the high-single to double-digit range. KT501 is an IgG-like tri-specific antibody that works by targeting CD3 on T cells and CD19 and BCMA on B cells—a binding pro Kali claims on its website enables the targeting of a broad range of B cell populations. The asset also makes use of a proprietary masking technology that maximizes its potency while minimizing cytokine release, which otherwise could lead to safety risks. KT501 is currently being tested in a first-in-human study for rheumatoid arthritis to assess its safety and tolerability as well as its pharmacokinetic and pharmacodynamic pro Kali dosed the first patient in this study last week. It is unclear what indications Sanofi plans to target, but the antibody “has the potential to treat a broad range of B cell–mediated autoimmune diseases,” according to the Monday announcement. Kali is the latest pickup in Sanofi’s recent immunology partnership push. Earlier this month, the pharma dropped an upfront sum of $135 million to collaborate with Hong Kong’s Sino Biopharmaceutical, gaining the right to advance and commercialize the oral drug rovadicitinib worldwide. Sino will be eligible for up to $1.395 billion in milestones. As in the case of Kali, Sanofi has yet to disclose what indications it plans to address with Sino, but rovadicitinib blocks the JAK and ROCK pathways, which play a role in immune balance. Immunology and inflammation Sanofi Bets Up to $1.53B in Hong Kong Immuno Pact, Adding to String of Deals Sanofi will gain global exclusive rights over rovadicitinib, an oral JAK/ROCK blocker that has anti-inflammatory and anti-fibrotic effects. March 4, 2026 · 2 min read · Tristan Manalac Read more In December 2025, Sanofi expanded its existing partnership with Dren Bio, betting up to $1.7 billion to leverage the biotech’s targeted myeloid engager and phagocytosis platform. Under the deal, Dren will discover novel multi-specific therapies, which Sanofi will then take forward into the clinic. Months earlier, Sanofi bought a B cell depleter from Dren for $600 million upfront and up to $1.3 billion in milestones. Two months earlier, Sanofi teamed up with EVOQ Therapeutics, putting up to $500 million on the line to use the biotech’s NanoDisc platform to develop therapies that selectively target dendritic cells.